Erythropoietin enhancement of rat pancreatic tumor cell proliferation requires the activation of ERK and JNK signals

American Journal of Physiology - Cell Physiology

Volumn 295, Issue 2, 2008, Pages

  Bose, Chhanda ^a,c   Udupa, Kodetthoor B ^a,b,c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

Cell signaling; Erythropoietin receptor; Mitogen activated protein kinase induction

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STRESS ACTIVATED PROTEIN KINASE; ANTIBODY; ELK1 PROTEIN, RAT; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 9; PROTEIN KINASE INHIBITOR; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE 1; TRANSCRIPTION FACTOR ELK 1;

ANIMAL CELL; ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; TUMOR CELL; ANIMAL; CELL CYCLE; DRUG ANTAGONISM; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; KINETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

RATTUS;

ANIMALS; ANTIBODIES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; ERYTHROPOIETIN; ETS-DOMAIN PROTEIN ELK-1; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; KINETICS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RATS; RECEPTORS, ERYTHROPOIETIN; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 55949103579     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00423.2007     Document Type: Article

References (72)

1. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, Verma A. Erythropoietin and erythropoietin receptor expression in human Cancer. Cancer Res 61: 3561-3565, 2001.
2. Acs G, Xu X, Chu C, Acs P, Verma A. Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer 100: 2376-2386, 2004.
3. Acs G, Zhang PJ, McGrath CM, Acs P, McBroom J, Mohyeldin A, Liu S, Lu Huasheng Verma A. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 162: 1789-1805, 2003.
4. Batra S, Perelman N, Luck LR, Shimada H, Malik P. Pediatric tumor cells express erythropoietin and a functional erythropoietic receptor that promotes angiogenesis and tumor cell survival. Lab Invest 83: 1477-1487, 2003.
5. Bose C, Zhang H, Udupa KB, Chowdhury P. Activation of p-ERK1/2 by nicotine in pancreatic tumor cell line AR42J: effects on proliferation and secretion. Am J Physiol Gastrointest Liver Physiol 289: G926-G934, 2005.
6. Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 95: 155-163, 2002.
7. Chang L, Karin M. Mammalian MAP kinase signaling cascades. Nature 410: 37-40, 2001.
8. Chen C, Sytkowski AJ. Erythropoietin activates two distinct signaling pathways required for the initiation and the elongation of c-myc. J Biol Chem 276: 38518-38526, 2001.
9. Chen C, Sytkowski AJ. Erythropoietin regulation of Raf-1 and MEK: evidence for a Ras-independent mechanism. Blood 104: 73-80, 2004.
10. Chowdhury P, Bose C, Udupa KB. Nicotine-induced proliferation of isolated rat pancreatic acinar cells: effect on cell signaling and function. Cell Prolif 40:125-141, 2007.
11. Cowley S, Paterson H, Kemp P, Marshall CJ. Activation of MAP kinase is both necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77: 841-852, 1994.
12. Damen JE, Mui AL, Puil JL, Pawson T, Krystal G. Phosphatidylinositol 3-kinase associates, via its Src homology 2 domains, with the activated erythropoietin receptor. Blood 81: 3204-3210, 1993.
13. D'Andrea AD, Lodish HF, Wong GG. Expression cloning of the erythropoietin receptor. Cell 57: 277-285, 1989.
14. Devemy E, Billat C, Haye B. Activation of Raf-1 and mitogen-activated protein kinases by erythropoietin and inositolphosphate-glycan in normal erythroid progenitor cells: involvement of protein kinase C. Cell Signal 9: 41-46, 1997.
15. Duan RD, Williams JA. Cholecystokinin rapidly activated mitogenactivated protein kinase in rat pancreatic acini. Am J Physiol Gastrointest Liver Physiol 267: G401-G408, 1994.
16. Du L, Lyle CS, Obey TB, Gaarde TB, Muir WA, Bennett JA, Bennett BL, Chambers TC. Inhibition of cell proliferation and cell cycle progression by specific inhibition of basal JNK activity. J Biol Chem 279: 11957-11966, 2004.
17. Dunlop EA, Percy MJ, Boland MP, Maxwell AP, Lappin TR. Induction of signaling in non-erythroid cells by pharmacological levels of erythropoietin. Neurodegener Dis 3: 94-100, 2006.
18. Elliott S, Busse L, Bass MB, Lu H, Sarosi L, Sinclair AM, Spahr C, Um M, Van G, Begley CG. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 107: 1892-1895, 2006.
19. Erbayraktar S, Yilmaz O, Gokeman N, Brimes M. Erythropoietin is a multifunctional tissue protective cytokine. Curr Hematol Rep 2: 465-470, 2003.
20. Fan M, Chambers TC. Role of mitogen activated protein kinase in the response of tumor cells to chemotherapy. Drug Resist Updat 5: 253-267, 2001.
21. Feldman L, Wang Y, Rhim JS, Bhattacharya N, Loda M, Sytkowski AJ. Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate 66: 135-145, 2006.
22. Gaffen SL, Lai SY, Longmore GD, Liu KD, Goldsmith MA. Genetic evidence for an additional factor required for erythropoietin-induced signal transduction. Blood 94: 74-86, 1999.
23. Gururajan M, Chui R, Karuppannan AK, Ke J, Jennings CD, Bondada S. c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. Blood 106: 1382-1391, 2005.
24. Hagemann C, Blank JL. The ups and downs of MEK kinase interactions. Cell Signal 13: 863-875, 2001.
25. Hardee M, Arcasoy M, Blackwell K, Kirkpatrick JP, Dewhirst MW. Erythropoietin biology in cancer. Clin Cancer Res 12: 332-339, 2006.
26. Hardee ME, Rabbani ZN, Arcasoy MO, Kirkpatrick JP, Vujaskovic Z, Dewhirst MW, Blackwell KL. Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Mol Cancer Ther 5: 356-361, 2006.
27. Hardee ME, Cao Y, Fu P, Jiang X, Zhao Y, Rabbani ZN, Vujaskovic Z, Dewhirst MW, Arcasoy MO. Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS ONE 2: e549, 2007.
28. Hideshima T, Hayashi T, Chauhan D, Akiyama M, Richardson P, Anderson K. Biologic sequelae of c-Jun NH2-terminal kinase (JNK) activation in multiple myloma cell lines. Oncogene 8: 2721-2729, 2003.
29. Jacobs-Helber SM, Penta K, Sun Z, Lawson A, Sawyer ST. Distinct signaling from stem cell factor and erythropoietin in HCD57 cells. J Biol Chem 272: 6850-6853, 1997.
30. Jacobs-Helber SM, Rayan JJ, Sawyer ST. JNK and p38 are activated by erythropoietin (EPO) but are not induced in apoptosis following EPO withdrawal in EPO dependent HCD57 cells. Blood 96: 933-940, 2000.
31. Jacobs-Helber SM, Sawyer ST. Jun N- terminal kinase promotes proliferation of immature erythroid cells and erythropoietin-dependent cell line. Blood 104: 696-703, 2004.
32. Kapur R, Chandra S, Cooper R, McCarthy J, Williams DA. Role of p38 and ERK MAP kinase in proliferation of erythroid progenitors in response to stimulation by soluble and membrane isoforms of stem cell factor. Blood 100: 1287-1293, 2002.
33. Kavurma MM, Khachigian LM. ERK, JNK, and p38 MAP kinase differentially regulate proliferation and migration of phenotypically distinct smooth muscle cell subtypes. J Cell Biochem 89: 289-300, 2003.
34. Kawano H, Kim S, Ohta K, Nakao T, Miyazaki H, Nakatani T, Iwao H. Differential contribution of three mitogen-activated protein kinase to PDGF-BB-induced mesenglial cell proliferation and gene expression. J Am Soc Nephrol 14: 584-592, 2003.
35. Kenneth M, Faqi L, Zhao ZC. New avenues of exploration for erythropoietin. JAMA 293: 90-95, 2005.
36. Kim HJ, Chakravarti N, Oridate N, Choe C, Claret FX, Lotan R. (4-Hydroxyphenyl) retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells. Oncogene 25: 2785-2794, 2006.
37. Kirkeby A, van Beek J, Nielsen J, Leist M, Helboe L. Functional and immunochemical characterization of different antibodies against the erythropoietin receptor. J Neurosci Methods 164: 50-58, 2007.
38. Komatsu N, Adamson JW, Yamamoto K, Altschuler D, Torti M, Marzocchini R, Lapetina EG. Erythropoietin rapidly induces tyrosine phosphorylation in the human erythropoietin-dependent cell line, UT-7. Blood 80: 53-59, 1992.
39. Krantz SB, Jacobson LO. Erythropoietin and the Regulation of Erythropoiesis. Chicago, IL: University of Chicago Press, 1970, p.106-116.
40. Kyosseva SV. Mitogen-activated protein kinase signaling. Int Rev Neurobiol 59: 201-220, 2004.
41. Kyriakis JM, Avruch. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. J Physiol Rev 81: 807-869, 2001.
42. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 74: 49-139, 1998.
43. Liu X, Yan S, Zhou T, Tereda Y, Erikson RL. The MAP kinase pathway is required for entry into mitosis and cell survival. Oncogene 23: 763-776, 2004.
44. Manning AM, Davis RJ. Targeting JNK for therapeutic benefit: From junk to gold. Nat Rev Drug Discov 2: 554-565, 2003.
45. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient verses sustained extracellular signal-regulated kinase activation domain. Cell 80:179 -185, 1995.
46. Mehrotra M, Krane SM, Walters K, Pilbeam C. Differential regulation of platelet-derived growth factor stimulated migration and proliferation in osteoblastic cells. J Cell Biochem 93: 741-752, 2005.
47. Mingo-Sion AM, Marietta PM, Koller E, Wolf DM, Berg CLVD. Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells. Oncogene 23: 596-604, 2004.
48. Mulcahy L. The erythropoietin receptor. Semin Oncol 28:19-23, 2001.
49. Nagata Y, Nishida E, Todokoro K. Activation of JNK signaling pathway by erythropoietin, thrombopoietin and interleukin-3. Blood 89: 2664-2669, 1997.
50. Nagata Y, Todokoro K. Requirement of activation of JNK and p38 for environmental stress-induced erythroid differentiation and apoptosis. Blood 94: 853-863, 1999.
51. Nagata Y, Takahashi N, Davis RJ, Todokoro K. Activation of p38 MAP kinase and JNK but not ERK is required for erythropoietin-induced erythroid differentiation. Blood 92: 1859-1869, 1998.
52. New L, Li Y, Ge B, Zhong H, Mansbridge J, Liu K, Han JJ. SB203580 promotes EGF- stimulated early morphological differentiation in PC12 cell through activating ERK pathway. J Cell Biochem 83: 585-596, 2001.
53. Nishigaki K, Hanson C, Thompson D, Yugawa Ruscetti S. Activation of the jun N-terminal kinase pathway by friend spleen focus-forming virus and its role in the growth and survival of friend virus-induced erythroleukemia cells. J Virol 79: 12752-12762, 2005.
54. Pajonk F, Weil A, Sommer A, Suwinski R, Henke M. The erythropoietin-receptor pathway modulates survival of cancer cells. Oncogene 23: 8987-8991, 2004.
55. Pelaia G, Gallelli L, D'Agostino B, Vatrella A, Cuda G, Fratto D, Renda T, Galderisi U, Piegari E, Crimi N, Rossi F, Caputi M, Costanzo FS, Vancheri C, Maselli R, Marsico SA. Effect of TGF-B and glucocorticoids on Map kinase phosphorylation, IL-6/IL-11 secretion and cell proliferation in primary cultures of human lung fibroblasts. J Cell Physiol 210: 489-497, 2007.
56. Pellegrino MJ, Stork PJ. Sustained activation of extracellular signalregulated kinase by nerve growth factor regulates c-fos protein stabilization and transactivation in PC12 cells. J Neurochem 99: 1480-1493, 2006.
57. Richmond TD, Chohan M, Barber DL. Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol 15: 146-155, 2005.
58. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeid J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS. Use of epoietin in patients with cancer: evidence based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 100: 2303-2320, 2002.
59. Satoru T, Takuya Y, Yoshiki T, Eisuke N. ERK MAP kinase in G1 cell cycle progression and cancer. Cancer Sci 97: 697-702, 2006.
60. Sawyer ST, Penta K. Association of JAK2 and STAT5 with erythropoietin receptor. Role of receptor phosphorylation in erythropoietin signal transduction. J Biol Chem 271: 32430-32437, 1996.
61. Schwabe RF, Bradham CA, Uehara T, Hatano E, Bennett B, Schoonhoven R, Bernner DA. c-Jun-N-terminal kinase drives cyclin D1 expression and proliferation during liver regeneration. Hepatology 37: 824-832, 2003.
62. Siren AL, Fratelli M, Brines M, Goemans C, Cassarande S, Lewczuk P, Keenan S, Gleiter C, Pasquali C, Capobianco A, Menniinj T, Heumann R, Cerami A, Ehrenreich H, Ghezzi P. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 98: 4044-4049, 2001.
63. Totri M, Marti KB, Altschuler D, Yamamoto K, Lapetina EG. Erythropoietin induces p21ras activation and p120GAP tyrosine phosphorylation in human erytroleukemia cells. J Biol Chem 267: 8293-8298, 1992.
64. Udupa KB. Functional significance of erythropoietin receptor on tumor cells. World J Gastroenterol 12: 7460-7462, 2006.
65. Udupa KB, Reissmann KR. In Vivo erythropoietin requirements of regenerating erythroid progenitors (BFU-e, CFU-e) in bone marrow of mice. Blood 53: 1164-1171, 1979.
66. Um M, Gross AW, Lodish HF. A classical homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Cell Signal 19: 634-645, 2006.
67. von Lindern M, Parren-van Amelsvoort M, van Dijk T, Deiner E, van den Akker E, van Emst-de Vries S, Willems P, Beug H, Lowenberg B. Protein kinase C alpha controls erythropoietin receptor signaling. J Biol Chem 275: 34719-34727, 2000.
68. Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 58: 647-657, 2000.
69. Yamaguchi K, Tomita H, Sugano E, Nakazawa T, Tamai M. Mitogen-activated protein kinase inhibitor, PD98059, inhibits rat retinal pigment epithelial cell replication by cell cycle arrest. Jpn J Ophthalmol 46: 634-639, 2002.
70. Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A, Onozaki M, Hashimoto M, Musha T, Ogawa K, Fujita H, Nakamura Y, Shiozaki H, Utsumi H. Erythropoietin regulates tumor growth of human malignancies. Carcinogenesis 24: 1021-1029, 2003.
71. Yasuda Y, Fujita Y, Masuda S, Musha T, Ueda K, Tanaka H, Fujita H, Matsuo T, Nagao M, Sasaki R, Nakamura Y. Erythropoietin is involved in growth and angiogenesis in malignant tumors of female reproductive organs. Carcinogenesis 23: 1797-1805, 2002.
72. Zhan Y, Kim S, Izumi Y, Izumiya Y, Nakao T, Miyazaki H, Iwao H. Role of JNK, p38, and ERK in platelet- derived growth factor-induced vascular proliferation, migration, and gene expression. Arterioscler Thromb Vasc Biol 23: 795-801, 2003.